Grimes & Company, Inc. Biogen Inc. Transaction History

Grimes & Company, Inc.

  • $3.43 Billion
  • Q4 2024

A detailed history of Grimes & Company, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 25,613 shares of BIIB stock, worth $3.69 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
25,613
Previous 47,467 46.04%
Holding current value
$3.69 Million
Previous $9.2 Million 57.44%
% of portfolio
0.11%
Previous 0.25%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 21, 2025
SELL
$146.47 - $191.55 $3.2 Million - $4.19 Million
-21,854 Reduced 46.04%
25,613 $3.92 Million
Q3 2024

Oct 22, 2024
SELL
$189.07 - $236.8 $51,616 - $64,646
-273 Reduced 0.57%
47,467 $9.2 Million
Q2 2024

Jul 22, 2024
BUY
$190.52 - $236.72 $162,323 - $201,685
852 Added 1.82%
47,740 $11.1 Million
Q1 2024

Apr 17, 2024
BUY
$212.02 - $267.71 $358,101 - $452,162
1,689 Added 3.74%
46,888 $10.1 Million
Q4 2023

Jan 24, 2024
BUY
$222.59 - $267.94 $140,009 - $168,534
629 Added 1.41%
45,199 $11.7 Million
Q3 2023

Oct 19, 2023
BUY
$253.3 - $285.89 $123,103 - $138,942
486 Added 1.1%
44,570 $11.5 Million
Q2 2023

Jul 19, 2023
SELL
$275.25 - $318.06 $111,201 - $128,496
-404 Reduced 0.91%
44,084 $12.6 Million
Q1 2023

Apr 20, 2023
SELL
$256.56 - $292.34 $396,898 - $452,249
-1,547 Reduced 3.36%
44,488 $12.4 Million
Q4 2022

Jan 25, 2023
SELL
$252.44 - $306.72 $173,173 - $210,409
-686 Reduced 1.47%
46,035 $0
Q3 2022

Oct 28, 2022
BUY
$194.69 - $268.46 $115,840 - $159,733
595 Added 1.29%
46,721 $12.5 Million
Q2 2022

Jul 22, 2022
BUY
$187.54 - $223.02 $175,912 - $209,192
938 Added 2.08%
46,126 $9.41 Million
Q1 2022

May 06, 2022
BUY
$193.77 - $244.14 $709,004 - $893,308
3,659 Added 8.81%
45,188 $9.52 Million
Q4 2021

Feb 01, 2022
SELL
$223.92 - $287.77 $69,863 - $89,784
-312 Reduced 0.75%
41,529 $9.96 Million
Q3 2021

Nov 08, 2021
SELL
$282.99 - $369.05 $3,678 - $4,797
-13 Reduced 0.03%
41,841 $11.8 Million
Q2 2021

Aug 04, 2021
SELL
$259.0 - $414.71 $51,023 - $81,697
-197 Reduced 0.47%
41,854 $14.5 Million
Q1 2021

May 12, 2021
BUY
$242.95 - $284.63 $811,695 - $950,948
3,341 Added 8.63%
42,051 $11.8 Million
Q4 2020

Feb 02, 2021
BUY
$236.26 - $355.63 $711,142 - $1.07 Million
3,010 Added 8.43%
38,710 $9.48 Million
Q3 2020

Nov 12, 2020
BUY
$264.77 - $305.71 $928,283 - $1.07 Million
3,506 Added 10.89%
35,700 $10.1 Million
Q2 2020

Jul 31, 2020
SELL
$258.66 - $342.55 $50,438 - $66,797
-195 Reduced 0.6%
32,194 $8.61 Million
Q1 2020

May 05, 2020
SELL
$268.85 - $341.04 $88,182 - $111,861
-328 Reduced 1.0%
32,389 $10.2 Million
Q4 2019

Feb 05, 2020
SELL
$220.06 - $304.07 $1.15 Million - $1.59 Million
-5,239 Reduced 13.8%
32,717 $9.71 Million
Q3 2019

Nov 05, 2019
BUY
$217.44 - $243.88 $7.87 Million - $8.83 Million
36,196 Added 2056.59%
37,956 $8.84 Million
Q2 2019

Jul 30, 2019
SELL
$219.29 - $241.72 $219,290 - $241,720
-1,000 Reduced 36.23%
1,760 $412,000
Q1 2019

May 02, 2019
BUY
$216.71 - $338.96 $216,710 - $338,960
1,000 Added 56.82%
2,760 $653,000
Q4 2018

Feb 01, 2019
SELL
$278.5 - $352.75 $81,322 - $103,003
-292 Reduced 14.23%
1,760 $530,000
Q3 2018

Nov 09, 2018
BUY
$293.51 - $383.83 $27,002 - $35,312
92 Added 4.69%
2,052 $725,000
Q2 2018

Aug 10, 2018
BUY
$257.52 - $306.91 $162,237 - $193,353
630 Added 47.37%
1,960 $569,000
Q1 2018

May 07, 2018
SELL
$260.13 - $367.91 $9,104 - $12,876
-35 Reduced 2.56%
1,330 $364,000
Q3 2017

Nov 03, 2017
BUY
$281.15 - $329.69 $383,769 - $450,026
1,365
1,365 $427,000

Others Institutions Holding BIIB

# of Institutions
998
Shares Held
130M
Call Options Held
1.12M
Put Options Held
1.43M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $20.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email